Title: Trastuzumab Combined with Chemotherapy in the Treatment for 40 Cases with Her-2-overexpressing Metastatic Breast Cancer
Abstract: [Purpose] To investigate the effect and toxicity of trastuzumab combined with vinorelbine based chemotherapy for Her-2-overexpressing metastatic breast cancer.[Methods] Forty cases with Her-2-overexpressing metastatic breast cancer,17 cases with Her-2(++) and 23 cases with Her-2(+++).The initial dose of trastuzumab was 4mg/kg,then once per week with 2mg/kg,at least 6 weeks.The dose of vinorelbine was 25mg/m2,d1;cisplatin was 70mg/m2,d1~3,every 21 days as a cycle.[Results] The overall response rate was 60%,6 cases in CR and 18 cases in PR.The main toxicity was fever and neutropenia(grade Ⅲ~Ⅳ).[Conclusion] Trastuzumab combined with vinorelbine-based chemotherapy for Her-2-overexpressing metastatic breast cancer is feasible and tolerable.
Publication Year: 2010
Publication Date: 2010-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot